Overview

Comparison of the Combination of Fenofibrate and Simvastatin Versus Atorvastatin

Status:
Completed
Trial end date:
2008-08-01
Target enrollment:
0
Participant gender:
All
Summary
Mixed or combined hyperlipidemia is a common metabolic disorder characterized by both hypercholesterolemia and hypertriglyceridemia. Statins and fibrates have complementary mechanisms and can be coadministered to patients with mixed hyperlipidemia. The overall objective of the study is to compare the efficacy and safety of combining fenofibrate and simvastatin versus atorvastatin monotherapy in patients with mixed hyperlipidemia at risk of cardiovascular diseases.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Solvay Pharmaceuticals
Treatments:
Atorvastatin
Atorvastatin Calcium
Fenofibrate
Simvastatin
Criteria
Inclusion Criteria:

- Mixed dyslipidemia.

Exclusion Criteria:

- Known hypersensitivity to fenofibrates or simvastatin or atorvastatin

- Pregnant or lactating women

- Contra-indication to fenofibrate or simvastatin or atorvastatin

- Unstable or severe cardiac disease